|Bid||102.85 x 100|
|Ask||103.30 x 100|
|Day's Range||102.00 - 103.05|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||24.06|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alexion, Gilead and Vertex are likely to beat the consensus' fourth-quarter model, an analyst predicted.
The earnings season will get its first taste of results from Silicon Valley, led by Netflix, Intel and other chip companies.
The biopharmaceutical company, whose biggest acquisition to date was Receptos in 2015 for $7.2 billion, recently agreed to pay up to $7 billion for Impact Biomedicines and reportedly is in talks for Juno, ...
M&A activity has begun in the New Year, with the pharma sector leading from the front. Earlier this week, the Wall Street Journal reported Celgene Corporation (NASDAQ: CELG ) is pursuing Juno Therapeutics ...
Celgene Corp. (NASDAQ:CELG), best known for the psoriasis medicine Otezla and a number of cancer drugs, like Revlimid and Vidaza, sent the stock of Juno Therapeutics Inc. (NASDAQ:JUNO) up 55% on Jan. 17 when it was reported to be buying it. An acquisition probably won’t change a lot for CELG stock. The rumored price for Juno would be $10-12 billion, not a big deal when Celgene is worth $80 billion, but Juno was only worth $5.6 billion on Jan. 12.
Depositary shares of the up-and-coming Chinese biotech firm BeiGene (BGNE) jumped 15% today, to $118, after the company successfully raised $750 million in a follow-on share offering. BeiGene has promising drugs under development, ample funding, and international partners like Celgene (CELG) and Boehringer Ingelheim. The Beijing-based drug developer is one of China’s leading hopes as that country tries to become one of the world’s medical innovators.
While Merck & Co., Inc. (NYSE:MRK) had gotten off to a modest pace to start the year, the last few trading sessions have been rather explosive. Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. All told, Merck stock is up more than 10% this year.
Juno Therapeutics Inc (NASDAQ:JUNO) stock is up about 50% after the Wall Street Journal reported on Tuesday that biotech giant Celgene Corporation (NASDAQ:CELG) is in talks to buy the company. Juno Therapeutics is a pioneer in the booming cell therapy industry, where biotech companies are developing modified human immune cells to combat cancer cells.
Mott Capital Management is a thematic growth fund that was founded in 2014 by Michael J. Kramer. Mr. Kramer manages a long-only thematic growth portfolio that has a stead and low turnover rate and contains an average of 20 stocks that are held over a period of up to five years. In addition to investing money on behalf […]
Stocks had a huge day, sending the major indexes to new records. Shares of Juno Therapeutics soared following a buyout report, and Ford slumped on disappointing guidance.
Shares of Juno Therapeutics Inc (NASDAQ: JUNO ) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG ) for an acquisition. ...
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal.